On Monday, January 8, 2024, Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., a clinical-stage bio-pharmaceutical company to design and develop next-generation antibody drug conjugates (ADCs) in a $2billion all-cash deal. The agreement was announced on the first day of the annual JP Morgan Healthcare Conference in San Francisco, California. Under the terms of the deal, Johnson & Johnson will pay $28 a share for Ambrx, or about double the firm’s Friday closing price of $13.63. Johnson & Johnson plans to finish the deal in the first half of 2024.

      Daniel J. O’Connor, Chief Executive Officer of Ambrx, made some positive comments “We are excited to reach this agreement with Johnson & Johnson for advancing scientific research to treat cancers with high unmet need. With our deep and unique knowledge of precision engineering of protein therapeutics enabled by our proprietary technology incorporating synthetic amino acids in living cells, Ambrx has developed next-generation novel drug candidates such as site-specifically conjugated highly stable antibody drug conjugates. Through this transaction, we will continue to advance our leading prostate cancer candidate and Ambrx’s promising pipeline, while delivering significant and certain cash value to our shareholders. This announcement is the culmination of two decades of scientific work, combined with the Ambrx team’s talent, hard work and innovation. I look forward to what Ambrx will achieve as part of Johnson & Johnson.”

     Ambrx is a clinical-stage biopharmaecutical company based in San Diego, California which is instrumental in designing and developing antibody drug conjugates (ADCs) to treat cancer. Ambrx has some cancer drugs and ARX517 is one of the key products, an ADC targeting prostate-specific membrane antigen for prostate cancer. Another key product is ARX788 to treat breast cancer. ARX305 is also being developed to target renal cell carcinoma.

  Founded in 1886 by three brothers, Johnson & Johnson (J&J) is an American multinational, pharmaceutical, and medical technologies corporation headquartered in New Jersey, and publicly traded on the New York Stock Exchange. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices markets. The Company sells products such as skin and hair products, over the-counter-products, prescription pharmaceuticals, and surgical implants in countries around the world. The most popular consumer brands include Band-Aids, Tylenol and Johnson's Baby Powder. Johnson & Johnson believes health is everything. In 2023, Johnson & Johnson revenue was $99.128B, a 7.46% increase year-over-year.

       On the ranking of “The 3rd Daguan·Keweiwei World Brand Value Top 900” released on March 18, 2023,  Johnson & Johnson’s brand value was 886.585 billion RMB, ranking the 8th. 

www.bvrcn.com  品牌价值网

          "(www.bvrcn. com) Daguan · Brand Value (China) Network" defines a fair China Brand Value Evaluation Standard in the world, lead the global brand news value, create a highland for the global brand value evaluation industry, and discover the release of the "Daguan · Keweiwei" World Brand Value Top 900 ranking list. It is also the globally preferred and trusted enterprise brand information website that fairly and justly recommends global brand enterprises, achieves the influence of brand value (China) network's global brand communication. It launches heavyweight brand value information, leads global brand hotspots, links global media communication camps, and establishes new coordinates for global brand news news communication. 

作者：Byron